aBLA Filing Intelligence & Biosimilar Opportunity

Tzield

Teplizumab-Mzwv

Immunomodulators

Injection Injectable

Approval Date

18-Nov-22

Data Exclusivity Expiry

18-Nov-26

Market Exclusivity Expiry

18-Nov-34

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.4616

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

126

2027

191

2028

273

2029

324

2030

346

2031

384

2032

417

Molecule profile

Details & specifications

Molecule

Teplizumab-Mzwv

Innovator

PROVENTION BIO, INC.

Dosage Form

Injection Injectable

Strength

2 mg/2 mL (1 mg/mL)

Therapeutic Category

Immunomodulators

Usage

To delay the onset of stage 3 type 1 diabetes

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.